LAG3 and neoplasm: Specific inhibitors of GALECTIN-3 have also been developed and these may represent an attractive alternative therapeutic strategy to block LAG-3 signalling as well as other potentially pro-tumourigenic biological functions of GALECTIN-3 such as promoting angiogenesis, tumour cell intra- and extravasation and metastasis41.